Recent advances in the treatment of diabetic neuropathy

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 2, 2006, Pages 147-153

  Casellini, Carolina M ^a   Vinik, Aaron I ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Diabetic neuropathy; Pain; Treatment

Indexed keywords

2 (4 BROMO 2 FLUOROBENZYL)SPIRO[1,2,3,4 TETRAHYDROPYRROLO[1,2 A]PYRAZINE 4,3' PYRROLIDINE] 1,2',3',5' TETRAONE; ALDOSE REDUCTASE INHIBITOR; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENFOTIAMINE; CARBAMAZEPINE; DEXTROMETHORPHAN; DIURETIC AGENT; DULOXETINE; GAMMA LINOLENIC ACID; LAMOTRIGINE; LOCAL ANESTHETIC AGENT; NERVE GROWTH FACTOR; NEUROTROPIN; NEUROTROPIN 3; PONALRESTAT; PREGABALIN; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; STEROID; THIOCTIC ACID; TOLRESTAT; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; ZENARESTAT;

AUTONOMIC NERVOUS SYSTEM; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DIZZINESS; HUMAN; MORBIDITY; MORTALITY; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; ORTHOTICS; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PILATES; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY; TAI CHI; UNITED STATES; XEROSTOMIA; YOGA;

EID: 33646041955     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000216963.51751.be     Document Type: Review

References (47)

1. Vinik A, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88:947-999. A complete review of the diagnosis and treatment of diabetic neuropathy, with useful tables and figures that aid in the differential diagnosis and correct selection of treatment.
2. Boulton A, Malik T, Arezzo JC, Sosenko J. Diabetic somatic neuropathies: technical review. Diabetes Care 2004; 27:1458-1486. An extensive review of the somatic diabetic neuropathies that includes pathogenesis and detailed descriptions of diagnostic methods.
3. Boulton AJ, Vinik A, Arezzo J, et al., for the American Diabetes Association. Position statement: diabetic neuropathies. Diabetes Care 2005; 28:956-962. The most up-to-date position statement from the American Diabetes Association in relation to diabetic neuropathy.
4. Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005; 28:1480-1481.
5. Vinik AI, Milicevic Z. Recent advances in the diagnosis and treatment of diabetic neuropathy. The Endocrinologist 1996; 6:443-461.
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-865.
8. Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus [abstract]. JAMA 2002; 287:2563-2569.
9. LeRoith D, Fonseca V, Vinik A. Metabolic memory in diabetes: focus on insulin. Diabetes Metab Res Rev 2005; 21:85-90.
10. Vinik A, Bril V, Kempler P, et al., for the MBBQ Study. Treatment of symptomatic diabetic peripheral neuropathy with protein kinase CB inhibitor ruboxistaurin mesylate during a 1-year randomized, placebo-controlled, double-blind clinical trial. Clin Therapeut 2005; 27:1164-1180.
11. Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21:114-121.
12. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352:341-350. A large, well designed multicenter study including 1172 patients to assess the influence of vascular risk factors on the development of diabetic neuropathy.
13. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
14. Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004; 27:2178-2183.
15. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a 'causal' antioxidant therapy. Diabetes Care 2003; 26:1589-1596.
16. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25:612-628.
17. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004; 3:173-189.
18. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005; 48:1637-1644.
19. Cameron NE, Gibson TM, Nangle MR, Cotter MA. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann NY Acad Sci 2005; 1043:784-792.
20. Hotta N, Shigeta Y, Sakamoto N, et al. Long-term effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: a 3-y multicenter comparative study, ARI-Diabetes Complications Trial (ADCT) [abstract]. Diabetes 2005; 54:A213.
21. Bril V, Buchanan RA. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2004; 27:2369-2375.
22. Vinik A, Kles K. Microvascular dysfunction. Curr Diabetes Rev 2005 (in press).
23. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272:728-731.
24. Nakamura J, Koh N, Hamada Y, et al. Effect of a protein kinase C-B specific inhibitor on diabetic neuropathy in rats [abstract]. Diabetes 1998; 47 (Suppl 1):A70.
25. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-B-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48:2090-2095.
26. Vinik AI, Bril V, Litchy WJ, et al., and the The MBBQ Study Group. Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. Muscle Nerve 2005; 32:619-625.
27. Vinik A, Pittenger G, Stansberry K, et al. Neurotrophic factors in diabetic neuropathy. Curr Opin Endocrinol Diabetes 2001; 8:205-212.
28. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154:355-363.
29. Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001; 107:1215-1218.
30. Sharma K, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002; 59:758-765.
31. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995; 52:1053-1061.
32. Barada A, Reljanovic M, Milicevic Z, et al. Proximal diabetic neuropathy: response to immunotherapy [abstract]. Diabetes 1999; 48 (Suppl 1): A148.
33. Granberg V, Ejskjaer N, Peakman M, Sundkvist G. Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care 2005; 28:1959-1964.
34. Vinik AI, Anandacoomaraswamy D, Ullal J. Antibodies to neuronal structures: innocent bystanders or neurotoxins? Diabetes Care 2005; 28:2067-2072. These data support a predictive role for the presence of antineuronal antibodies on the later development of neuropathy.
35. Milicevic Z, Newlon PG, Pittenger GL, et al. Anti-ganglioside GM1 antibody and distal symmetric 'diabetic polyneuropathy' with dominant motor features. Diabetologia 1997; 40:1364-1365.
36. Schroeder C, Vernino S, Birkenfeld AL, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med 2005; 353:1585-1590.
37. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116:109-118.
38. Raskin J, Pritchett JL, Wang F, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of diabetic peripheral neuropathic pain [abstract]. Diabetes 2005; 54:A126.
39. Vinik AI. Advances in diabetes for the millennium: new treatments for diabetic neuropathies. Med Gen Med 2004; 6:13.
40. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291:605-614.
41. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110:628-638.
42. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63:2104-2110.
43. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115:254-263.
44. Raskin P, Donofrio P, Rosenthal N, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004; 63:865-873.
45. Vinik A, Pittenger G, Anderson A, et al. Topiramate improves C-fiber neuropathy and features of the dysmetabolic syndrome in type 2 diabetes [abstract]. Diabetes 2003; 52 (Suppl 1):A130.
46. Vinik A. Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005; 90:4936-4945. A complete review of the different antiepileptic drugs available for the treatment of diabetic neuropathy.
47. Liu-Ambrose T, Khan KM, Eng JJ, et al. Resistance and agility training reduce fall risk in women aged 75 to 85 with low bone mass: a 6-month randomized, controlled trial. J Am Geriatr Soc 2004; 52:657-665.